NHE-1 is usually highly expressed in prostate cancers and correlates with the expression of transcription factors, such as Zeb1, which promote the mesenchymal transition and, consequently, the invasion and metastatic potential of the tumor lesions [48]. Here, SLC9A1 is linked to prostate carcinoma.